The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Open accessAbstract
Cost-of-illness studies, the systematic quantification of the economic burden of diseases on the individual and on society, help illustrate direct budgetary consequences of diseases in the health system and indirect costs associated with patient or carer productivity losses. In the context of the BURQOL-RD project ("Social Economic Burden and Health-Related Quality of Life in patients with Rare Diseases in Europe") we studied the evidence on direct and indirect costs for 10 rare diseases (Cystic Fibrosis [CF], Duchenne Muscular Dystrophy [DMD], Fragile X Syndrome [FXS], Haemophilia, Juvenile Idiopathic Arthritis [JIA], Mucopolysaccharidosis [MPS], Scleroderma [SCL], Prader-Willi Syndrome [PWS], Histiocytosis [HIS] and Epidermolysis Bullosa [EB]). A systematic literature review of cost of illness studies was conducted using a keyword strategy in combination with the names of the 10 selected rare diseases. Available disease prevalence in Europe was found to range between 1 and 2 per 100,000 population (PWS, a sub-type of Histiocytosis, and EB) up to 42 per 100,000 population (Scleroderma). Overall, cost evidence on rare diseases appears to be very scarce (a total of 77 studies were identified across all diseases), with CF (n=29) and Haemophilia (n=22) being relatively well studied, compared to the other conditions, where very limited cost of illness information was available. In terms of data availability, total lifetime cost figures were found only across four diseases, and total annual costs (including indirect costs) across five diseases. Overall, data availability was found to correlate with the existence of a pharmaceutical treatment and indirect costs tended to account for a significant proportion of total costs. Although methodological variations prevent any detailed comparison between conditions and based on the evidence available, most of the rare diseases examined are associated with significant economic burden, both direct and indirect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Epidemiologic Transition: A Theory of the Epidemiology of Population Change
OMRAN, A. R. (2005) · The Milbank Quarterly · doi:10.1111/j.1468-0009.2005.00398.x · Cited by 3,823
Vanier, M. T. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-16 · Cited by 1,222
McDonald, C. M., Abresch, R. T., Carter, G. T., Fowler, W. M., Johnson, E. R., Kilmer, D. D., & Sigford, B. J. (1995) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199509001-00003 · Cited by 1,069
Robinson, R. (1993) · BMJ · doi:10.1136/bmj.307.6907.793 · Cited by 816
Cost-of-Illness Methodology: A Guide to Current Practices and Procedures
Hodgson, T. A., & Meiners, M. R. (1982) · The Milbank Memorial Fund Quarterly. Health and Society · doi:10.2307/3349801 · Cited by 668
Cost-of-Illness Studies: A Major Headache?
Drummond, M. (1992) · PharmacoEconomics · doi:10.2165/00019053-199202010-00001 · Cited by 489
Garber, K. B., Visootsak, J., & Warren, S. T. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.61 · Cited by 473
Gringeri, A., Mantovani, L. G., Scalone, L., Mannucci, P. M., & the COCIS Study Group (2003) · Blood · doi:10.1182/blood-2003-03-0941 · Cited by 372
Cost of illness studies: What is good about them?
Rice, D. P. (2000) · Injury Prevention · doi:10.1136/ip.6.3.177 · Cited by 349
Butler, J. V., Whittington, J. E., Holland, A. J., Boer, H., Clarke, D., & Webb, T. (2002) · Developmental Medicine and Child Neurology · doi:10.1017/s001216220100202x · Cited by 343
Cited by
The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities
Chong, J. X., Buckingham, K. J., Jhangiani, S. N., Boehm, C., Sobreira, N., Smith, J. D., Harrell, T. M., McMillin, M. J., Wiszniewski, W., Gambin, T., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.06.009 · Cited by 643
The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review
Ryder, S., Leadley, R. M., Armstrong, N., Westwood, M., de Kock, S., Butt, T., Jain, M., & Kleijnen, J. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0631-3 · Cited by 530
Ferreira, C. R. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61124 · Cited by 498
Gammie, T., Lu, C. Y., & Babar, Z. U.-D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140002 · Cited by 277
A Systematic Review of Cost-of-Illness Studies of Multimorbidity
Wang, L., Si, L., Cocker, F., Palmer, A. J., & Sanderson, K. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-017-0346-6 · Cited by 178
Metadata
- Authors
- Angelis, A., Tordrup, D., & Kanavos, P.
- Venue
- Health Policy
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 119
- Issue
- 7
- Pages
- 964-979
- ISSN
- 0168-8510 (ISSN-L)
- OpenAlex
- W2069310265
- Cited by
- 306
- References
- 53
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. https://app.cochat.ai/papers/10.1016/j.healthpol.2014.12.016
- The paper
- Angelis, A., Tordrup, D., & Kanavos, P. (2015). Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. https://doi.org/10.1016/j.healthpol.2014.12.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.